SavedAdd your journal

Journals / Journal of advances in vetbio science and techniques / 2017 / Cilt: 2 - Sayı: 2

Should pimobendan always be used in congenital heart failure in dog and cats?

Köpek ve kedilerde konjestif kalp yetmezliklerinde her daim pimobendan kullanılmalı mı?

Songül Toplu
Kerem Ural
Sezen Doğan
Pages
24–29
Publication Date
2017-08-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, it can be suggested that safe use of pimobendan is not inconvenient unless it is used except in indications.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Pimobendan has a positive inotropic and vasodilatory effect by sensitization of calcium and inhibiton of phosphodiesterase III enzyme.
📊
Key Findings & Data:It is widely used for treatment of congestive heart failure from chronic valvular disease or dilated cardiomyopathy both human and veterinary medicine.
💡
Conclusion & Impact:Therefore, it can be suggested that safe use of pimobendan is not inconvenient unless it is used except in indications.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Pimobendan · Kedi · Köpek

Abstract

Pimobendan has a positive inotropic and vasodilatory effect by sensitization of calcium and inhibiton of phosphodiesterase III enzyme. It is widely used for treatment of congestive heart failure from chronic valvular disease or dilated cardiomyopathy both human and veterinary medicine. Positive findings have advised about pimobendan association with increasing life quality, reducing heart failure score and increasing survival time, however, potential side effects also available. Studies of pimobendan uses in cats are underway to further assess. Therefore, it can be suggested that safe use of pimobendan is not inconvenient unless it is used except in indications.

Özet

Pimobendan pozitif inotropik ve vazodilatatör etkilerini kalsiyuma karşı duyarlılığı arttırarak ve fosfodiesteraz III enzim inhibisyonu ile gerçekleştirmektedir. Hem beşeri hem de veteriner hekimliği alanında kronik kapakçık yetmezliği ve dilate kardiyomiyopatiden kaynaklanan konjestif kalp hastalıklarının tedavisinde yaygın olarak kullanılmaktadır. Yaşam kalitesini arttırma, kalp yetmezliği skorlamasında azalma ve yaşam süresini uzatma ile ilişkili pozitif bulgularından bahsedilirken potansiyel yan etkileri de bulunmaktadır. Kedilerde pimobendan kullanımına yönelik araştırmalar halen devam etmektedir. Sonuç olarak endike olduğu durumlar dışında kullanılmadığı sürece, pimobendanın güvenle kullanılmasının sakıncalı olmadığı öne sürülebilir.

🔖

Cite This Article

Toplu, S., Ural, K., Doğan, S. (2017). Should pimobendan always be used in congenital heart failure in dog and cats?. Journal of advances in vetbio science and techniques, Cilt: 2 - Sayı: 2, 24–29. https://ajindex.com/articles/676938

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Amberger, C., Chetboul, V., Bomassi, E., Rougier, S., Woehrlé, F., Thoulon, F. (2004): Comparison of the effects of imidapril and enalapril in a prospective, multicentric randomized trial in dogs with naturally acquired heart failure. J Vet Cardiol 6(2), 9-16.
  2. Asanoi, H., Ishizaka, S., Kameyama, T., Ishise, H., Sasayama, S. (1994): Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure. J Cardiovasc Pharmacol 23(2), 268-274.
  3. Atkins, C., Bonagura, J., Ettinger, S., Fox, P., Gordon, S., Haggstrom, J., Stepien, R. (2009): Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 23(6), 1142-1150.
  4. Boswood, A., Häggström, J., Gordon, S.G., Wess, G., Stepien, R.L., Oyama, M.A., Smith, S. (2016): Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: The EPIC Study—a randomized clinical trial. J Vet Intern Med 30(6), 1765-1779.
  5. Bowles, D. (2011): Pimobendan and its use in treating canine congestive heart failure. Cardiology 33(11), 1-6.
  6. Buchanan, J.W. (1999): Prevalence of cardiovascular disorders. In: Fox, P.R., Sisson, D, Moise, N.S., (eds), Textbook of Canine and Feline Cardiology. Philadelphia, Saunders, W.B. 457–470.
  7. Chetboul, V., Lefebvre, H.P., Sampedrano, C.C., Gouni, V., Saponaro, V., Serres, F., Pouchelon, J.L. (2007): Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, and randomized study. J Vet İntern Med 21(4), 742-753.
  8. Fitton, A., Brogden, R.N. (1994): Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure. Drugs Aging 4, 417–441.
  9. Fox, P.R., Petrie, J.P., Liu, S.K., Hayes, K.C., Bond, B.R. (1997): Clinical and pathologic features of cardiomyopathy characterized by myocardial failure in 49 cats, 1990-1995. J Vet Intern Med 11, 139. Fuentes, V.L., Corcoran, B., French, A., Schober, K.E., Kleemann, R., Justus, C. (2002): A double‐blind, randomized, placebo‐controlled study of pimobendan in dogs with dilated cardiomyopathy. J Vet Intern Med 16(3), 255-261.
  10. Fujimoto, S., Matsuda, T. (1990): Effects of pimobendan, a cardiotonic and vasodilating agent with phosphodiesterase inhibiting properties, on isolated arteries and veins of rats. J Pharmacol Exp Ther 252, 1304–1311.
  11. Gordon, S.G., Miller, M.W., & Saunders, A.B. (2006): Pimobendan in heart failure therapy–a